Home Fairfield Boehringer Ingelheim and Eli Lilly team for new heart-failure drug trials

Boehringer Ingelheim and Eli Lilly team for new heart-failure drug trials

SHARE

Boehringer Ingelheim and Eli Lilly and Co. are expanding their clinical trial program for the diabetes drug Jardiance by evaluating the drug’s effect on exercise ability and heart failure symptoms in people with chronic heart failure.

Photo courtesy of Boehringer Ingelheim

This new endeavor consists of two Phase III randomized, double-blind trials that evaluate the effect of 12 weeks of treatment with a once-daily dosage of Jardiance 10 mg versus a placebo on exercise ability and heart failure symptoms in patients with chronic heart failure with preserved or reduced ejection fraction. The tests will be measured by the 6-minute walking exercise.

“Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can improve patient health outcomes and fill treatment gaps to serve as a broad cardiometabolic treatment option,” said Thomas Seck, vice president of clinical development and medical affairs – primary care, at the Ridgefield-based Boehringer Ingelheim Pharmaceuticals Inc.

Print Friendly, PDF & Email

LEAVE A REPLY

Please enter your comment!
Please enter your name here